Atorvastatin Reduces Proteinuria in Non-Diabetic Chronic Kidney Disease Patients Partly via Lowering Serum Levels of Advanced Glycation End Products (AGEs)

There is accumulating evidence that advanced glycation end products (AGEs) play a role in the development and progression of chronic kidney disease (CKD). We have previously found that atorvastatin treatment significantly reduces serum levels of AGEs in type 2 diabetic patients and subjects with non...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tsukasa, Sato, Eiichi, Fujiwara, Nobuharu, Kawagoe, Yasuhiro, Takeuchi, Masayoshi, Maeda, Sayaka, Yamagishi, Sho-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154036/
https://www.ncbi.nlm.nih.gov/pubmed/21150335
http://dx.doi.org/10.4161/oxim.3.5.13069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154036/
https://www.ncbi.nlm.nih.gov/pubmed/21150335
http://dx.doi.org/10.4161/oxim.3.5.13069

Ejemplares similares